CSL Behring Presents New Phase III Analysis of IDELVION® for Hemophilia B at the 2016 American Society of Hematology Annual Meeting Dec 3, 2016 08:30PM

SAN DIEGO, Dec. 3, 2016  /PRNewswire/ -- Global biotherapeutics leader CSL Behring today announced new results from its Phase III clinical development program evaluating IDELVION® [Coagulation Factor IX (Recombinant), Albumin Fusion Protein], the company's novel, long-acting recombinant albumin fusion protein for the treatment of hemophilia B. The results, from a pooled analysis of clinical studies from the global PROLONG-9FP program, assessed the... (continue reading...)


Novartis presents results from first global registration trial of CTL019 in pediatric and young adult patients with r/r B-ALL Dec 3, 2016 07:07PM

EAST HANOVER, N.J., Dec. 3, 2016 /PRNewswire/ -- Findings from a Novartis clinical trial (ELIANA) evaluating efficacy and safety of CTL019, an investigational chimeric antigen receptor T cell (CAR T) therapy, in relapsed/refractory (r/r) pediatric and young adult patients with B-cell acute lymphoblastic leukemia (ALL) will be presented today during an oral session at the 58th American Society of Hematology (ASH) annual meeting (Abstract #221, December 3, 4:00-5:30... (continue reading...)


In Clinical Trials, CAR T Cell Immunotherapy Continues to Yield Complete Responses in Children & Young Adults with Relapsed and Refractory Leukemia Dec 3, 2016 07:05PM

SAN DIEGO, Dec. 3, 2016 /PRNewswire-USNewswire/ -- A highly innovative, personalized cell-based treatment for a high-risk form of the most common childhood cancer continues to move through clinical trials. Pediatric oncologists from Children's Hospital of Philadelphia today reported new results using T cell immunotherapy against relapsed or refractory acute lymphoblastic leukemia (ALL).

The physician-scientists presented findings at the annual meeting of the... (continue reading...)


Data at ASH 2016 Show Strong, Lasting Efficacy of IMBRUVICA® (ibrutinib) Through Five Years of Treatment for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Dec 3, 2016 07:05PM

SAN DIEGO AND RARITAN, N.J., Dec. 3, 2016 /PRNewswire/ -- Today, Janssen Research & Development, LLC (Janssen) announced the longest follow-up results to date of patients treated with IMBRUVICA® (ibrutinib) for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), showing high and lasting responses through five years. These updated Phase 1b/2 data demonstrated an overall response rate (ORR) of 89%, including patients with genetic mutations associated... (continue reading...)


Novartis presents results from first global registration trial of CTL019 in pediatric and young adult patients with r/r B-ALL Dec 3, 2016 07:00PM

Novartis International AG / Novartis presents results from first global registration trial of CTL019 in pediatric and young adult patients with r/r B-ALL . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement.

  • 82% (41 of 50) of patients achieved complete remission or complete remission with incomplete blood count recovery in interim analysis of Novartis study (ELIANA)

More Press Releases

View Older Stories

Dec 3, 2016 07:00PM IMBRUVICA® (ibrutinib) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 5-Year Analysis and Long-Term RESONATE-2 Follow-up Data at ASH 2016 Show Lasting Efficacy
Dec 3, 2016 06:30PM Celgene Corporation, Dana-Farber Cancer Institute and University of Arkansas for Medical Sciences Establish the Myeloma Genome Project
Dec 3, 2016 05:45PM Preclinical Data on Proprietary AKT Inhibitor, ARQ 092, Demonstrating Effectiveness in the Treatment of Sickle Cell Disease Presented at the American Society of Hematology Annual Meeting
Dec 3, 2016 05:00PM Takeda and Seattle Genetics Report Positive Phase 3 ALCANZA Clinical Trial Data of ADCETRIS® (Brentuximab Vedotin) for CD30-Expressing Cutaneous T-Cell Lymphoma
Dec 3, 2016 04:53PM Government of Canada Announces Concrete Action on Marine Conservation
Dec 3, 2016 04:29PM Dr. Andre Goy and Cota will present "Impact of Charlson Comorbidity Index (CCI) and Refining the MIPI Index in Mantle Cell Lymphoma" at 58th American Society of Hematology Annual Meeting &am
Dec 3, 2016 04:27PM National Fire Sprinkler Association Emphasizes the need for the Fire Sprinkler Incentive Act Following Tragic Oakland, CA Fire
Dec 3, 2016 03:52PM uniQure Announces First Clinical Data From Second Dose Cohort of AMT-060 in Ongoing Phase I/II trial in Patients with Severe Hemophilia B
Dec 3, 2016 03:35PM St. Jude Memphis Marathon® Weekend raises $10 million for kids battling cancer, other life-threatening diseases at St. Jude Children's Research Hospital®
Dec 3, 2016 03:11PM His Holiness Pope Francis Addresses Time Inc.’s 2016 Fortune/Time Global Forum at the Vatican
Dec 3, 2016 03:00PM Call of Duty World League (CWL), Presented by PlayStation®4, Kicks-off New Season with Invitational Tournament at PlayStation Experience (PSX)
Dec 3, 2016 03:00PM Studies Advance a More Personalized Approach to Treatment
Dec 3, 2016 03:00PM Seattle Genetics Presents Phase 1b Data from Vadastuximab Talirine (SGN-CD33A; 33A) in Combination with Standard of Care in Frontline Acute Myeloid Leukemia at ASH Annual Meeting
Dec 3, 2016 02:54PM Ocwen Announces Results of Previously Announced Exchange Offer
Dec 3, 2016 02:00PM Carando and TOPS Partner to Donate Spiral Sliced Hams to the Food Bank of Western New York
Dec 3, 2016 01:13PM Novartis SEG101 (crizanlizumab, formerly SelG1) significantly reduces frequency of sickle cell pain crises in Phase II study
Dec 3, 2016 01:00PM Novartis SEG101 (crizanlizumab, formerly SelG1) significantly reduces frequency of sickle cell pain crises in Phase II study
Dec 3, 2016 01:00PM Sickle Cell Disease Research Shows Progress in Preventing Related Complications and Death
Dec 3, 2016 01:00PM Seattle Genetics Presents Data from Phase 2 Study Evaluating ADCETRIS® (Brentuximab Vedotin) in Frontline Diffuse Large B-cell Lymphoma at ASH Annual Meeting
Dec 3, 2016 01:00PM Pairnomix Presents Systematic Approach To Identifying Approved Drugs That May Be Repurposed For Treatment Of Rare Genetic Diseases
Dec 3, 2016 01:00PM New Phase 2 Results Show Investigational Compound Glasdegib Improved Overall Survival in Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
Dec 3, 2016 12:35PM Hainan Airlines Launches Beijing-Las Vegas Non-stop Service
Dec 3, 2016 12:35PM Control Of The Tan Company, MassageLuXe, Xist Fitness, LifeXist And BAM Brands Turned Over To Mark Otter
Dec 3, 2016 12:30PM True North Presents Additional Data from an Ongoing Clinical Study Showing Normalization of Hemoglobin Levels with TNT009 in Severely Anemic Cold Agglutinin Disease (CAD) Patients
Dec 3, 2016 12:02PM Alnylam Reports Positive Interim Phase 1 Results for Fitusiran in Hemophilia A and B Patients with Inhibitors
Dec 3, 2016 12:00PM Trillium Presents Initial Data From Ongoing Study of TTI-621 in Patients With Advanced Hematologic Malignancies at the American Society of Hematology Annual Meeting
Dec 3, 2016 12:00PM Aduro Biotech Presents Preclinical Data Supporting Clinical Development of its Anti-APRIL Antibody, BION-1301, for the Treatment of Multiple Myeloma
Dec 3, 2016 12:00PM Elizabeth Dipp Metzger Qualifies for the NAIFA Award for 2016
Dec 3, 2016 12:00PM bluebird bio Presents New Data from HGB-205 Study of LentiGlobinTM Drug Product in Patients with Transfusion-Dependent β-Thalassemia (TDT) and Severe Sickle Cell Disease at American Society of Hemato
Dec 3, 2016 12:00PM Alnylam Reports Positive Initial Clinical Activity Results for Givosiran (ALN-AS1), an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias
Dec 3, 2016 12:00PM Bellicum Announces Updated Clinical Data from BPX-501 Study in Children with Primary Immune Deficiencies and Hemoglobinopathies
Dec 3, 2016 11:05AM After One Dose of Gene Therapy, Hemophilia B Patients Maintain Near-Normal Levels of Clotting Factor
Dec 3, 2016 11:00AM Spark Therapeutics and Pfizer Present Updated Preliminary Data from Hemophilia B Phase 1/2 Trial Suggesting Consistent and Sustained Levels of Factor IX Activity at Annual ASH Meeting
Dec 3, 2016 11:00AM Three Surprising Stats Igniting Demand for Health Care Video in 2017
Dec 3, 2016 11:00AM Bioengineering Innovations Show Promise for Improving Treatments and Drug Delivery
Dec 3, 2016 11:00AM Maserati Partners With Sotheby's To Celebrate "Night Of Luxury" In New York City
Dec 3, 2016 10:45AM Juno Therapeutics Announces Complete Response and Corresponding Early Survival Data for JCAR014 in Patients with Ibrutinib-Refractory CLL
Dec 3, 2016 10:30AM Atara Bio Announces Results from Ongoing Phase 2 Trial of Allogeneic Cytomegalovirus (CMV)-specific Cytotoxic T Lymphocytes (CTL) at the American Society of Hematology (ASH) Annual Meeting 2016
Dec 3, 2016 10:18AM Travelzoo Named World's Leading Travel Deals Website at the 2016 World Travel Awards
Dec 3, 2016 10:05AM Inventor and InventHelp Client Designs Alternative Music System to Pump Up Hockey Teams (TOR-9619)
Dec 3, 2016 09:45AM InventHelp Inventor Develops Tool for Running Wires through Conduit (TOR-9608)
Dec 3, 2016 09:45AM TIME SAVER Serves as an Alternative Charging/Power System - Designed by InventHelp Client (TOR-9590)
Dec 3, 2016 09:35AM Inventor and InventHelp Client Develops Improved Car Seat for Young Children (TEN-105)
Dec 3, 2016 09:25AM Cell Phone Charger Invented for Bicycles - Designed by InventHelp Client (STU-2115)
Dec 3, 2016 09:15AM WIMP'S SPACE SAVER AND GARAGE ORGANIZER Invented by InventHelp Client (STU-2109)
Dec 3, 2016 09:05AM InventHelp Client's System Facilitates Emptying of an RV's Black-Water Tank (SKC-185)
Dec 3, 2016 09:00AM United Airlines Starts Service between Houston and Havana, Cuba
Dec 3, 2016 08:55AM Water Conservation System Invented for Showers - Designed by InventHelp Client (SFO-291)
Dec 3, 2016 08:45AM InventHelp Invention Prevents Pillows from Falling Off Beds (SFO-275)
Dec 3, 2016 08:35AM InventHelp Inventor Develops Toilet-Bowl Accessory for Improved Hygiene (SFO-260)
View Older Stories